The biological half-life of a biological substance is the time it takes for half to be removed by biological processes. This concept is used when the rate of removal is roughly exponential. It is often denoted by the abbreviation . This is used to measure the removal of things such as metabolites, drugs, and signalling molecules from the body. Typically, the biological half-life refers to the body's natural cleansing through the function of the liver and through the excretion of the measured substance through the kidneys and intestines.
In a medical context, half-life explicitly describes the time it takes for the blood plasma concentration of a substance to halve (plasma half-life) its steady-state when circulating in the full blood of an organism. This measurement is useful in medicine and pharmacology because it helps determine how much of a drug needs to be taken and how frequently it needs to be taken if a certain average amount is needed constantly. In contrast, the stability of a substance direct in plasma is described with plasma stability that is essential to ensure accurate analysis of drugs in plasma and for Drug discovery.
The relationship between the biological and plasma half-lives of a substance can be complex depending on the substance in question, due to factors including accumulation in tissues (protein binding), active metabolites, and receptor interactions.
The biological half-life of water in a human is about 7 to 14 days. It can be altered by behavior. Drinking large amounts of alcohol will reduce the biological half-life of water in the body. This has been used to decontaminate humans who are internally contaminated with tritiated water (tritium). The basis of this decontamination method (used at Harwell) is to increase the rate at which the water in the body is replaced with new water.
The removal of ethanol (drinking alcohol) through oxidation by alcohol dehydrogenase in the liver from the human body is limited. Hence the removal of a large concentration of alcohol from blood may follow zero-order kinetics. Also the rate-limiting steps for one substance may be in common with other substances. For instance, the blood alcohol concentration can be used to modify the biochemistry of methanol and ethylene glycol. In this way the oxidation of methanol to the toxic formaldehyde and formic acid in the human body can be prevented by giving an appropriate amount of ethanol to a person who has ingested methanol. Note that methanol is very toxic and causes blindness and death. A person who has ingested ethylene glycol can be treated in the same way. Half life is also relative to the subjective metabolic rate of the individual in question.
|Adenosine||Less than 10 seconds|
|Norepinephrine||2 minutes|
|Salbutamol||1.6 hours|
|Zaleplon||1–2 hours|
|Morphine||2–3 hours|
|Methotrexate||3–10 hours (lower doses),
8–15 hours (higher doses)
|Phenytoin||12–42 hours|
In rare cases up to 8 days
|Buprenorphine||16–72 hours|
|Clonazepam||18–50 hours|
Active metabolite, desflurazepam 1.75–10.4 days
|Donepezil||3 days|
Active lipophilic metabolite 4–16 days
|Amiodarone||25–110 days|
|Dutasteride||35 days|
|Bedaquiline||165 days|
The biological half-life of caesium in humans is between one and four months. This can be shortened by feeding the person prussian blue. The prussian blue in the digestive system acts as a solid ion exchanger which absorbs the caesium while releasing potassium ions.
For some substances, it is important to think of the human or animal body as being made up of several parts, each with their own affinity for the substance, and each part with a different biological half-life (physiologically-based pharmacokinetic modelling). Attempts to remove a substance from the whole organism may have the effect of increasing the burden present in one part of the organism. For instance, if a person who is contaminated with lead is given EDTA in a chelation therapy, then while the rate at which lead is lost from the body will be increased, the lead within the body tends to relocate into the brain where it can do the most harm.
Some substances may have different half-lives in different parts of the body. For example, oxytocin has a half-life of typically about three minutes in the blood when given intravenously. Peripherally administered (e.g. intravenous) peptides like oxytocin cross the blood-brain-barrier very poorly, although very small amounts (< 1%) do appear to enter the central nervous system in humans when given via this route. In contrast to peripheral administration, when administered intranasally via a nasal spray, oxytocin reliably crosses the blood–brain barrier and exhibits psychoactive effects in humans. In addition, also unlike the case of peripheral administration, intranasal oxytocin has a central duration of at least 2.25 hours and as long as 4 hours. In likely relation to this fact, endogenous oxytocin concentrations in the brain have been found to be as much as 1000-fold higher than peripheral levels.
Half-times apply to processes where the elimination rate is exponential. If is the concentration of a substance at time , its time dependence is given by
The half-life for this process is
In clinical practice, this means that it takes 4 to 5 times the half-life for a drug's serum concentration to reach steady state after regular dosing is started, stopped, or the dose changed. So, for example, digoxin has a half-life (or t½) of 24–36 h; this means that a change in the dose will take the best part of a week to take full effect. For this reason, drugs with a long half-life (e.g., amiodarone, elimination t½ of about 58 days) are usually started with a loading dose to achieve their desired clinical effect more quickly.
Many drugs follow a biphasic elimination curve — first a steep slope then a shallow slope:
The longer half-life is called the terminal half-life and the half-life of the largest component is called the dominant half-life. For a more detailed description see Pharmacokinetics § Multi-compartmental models.
|Dose||Amount of drug administered.||Design parameter||500 mmol|
|Dosing interval||Time between drug dose administrations.||Design parameter||24 h|
|Cmax||The peak plasma concentration of a drug after administration.||Direct measurement||60.9 mmol/L|
|tmax||Time to reach Cmax.||Direct measurement||3.9 h|
|Cmin||The lowest (trough) concentration that a drug
reaches before the next dose is administered.
|Direct measurement||27.7 mmol/L|
|Volume of distribution||The apparent volume in which a drug is distributed
(i.e., the parameter relating drug concentration
in plasma to drug amount in the body).
|Concentration||Amount of drug in a given volume of plasma.||83.3 mmol/L|
|Elimination half-life||The time required for the concentration
of the drug to reach half of its original value.
|Elimination rate constant||The rate at which a drug is removed from the body.||0.0578 h−1|
|Infusion rate||Rate of infusion required to balance elimination.||50 mmol/h|
|Area under the curve||The integral of the concentration-time curve
(after a single dose or in steady state).
|Clearance||The volume of plasma cleared of the drug per unit time.||0.38 L/h|
|Bioavailability||The systemically available fraction of a drug.||Unitless||0.8|
|Fluctuation||Peak trough fluctuation within one dosing interval at steady state.||
Oxytocin can be delivered to humans via nasal spray following which it crosses the blood–brain barrier. ... In a double-blind experiment, oxytocin spray increased trusting behavior compared to a placebo spray in a monetary game with real money at stake.
Recent studies also highlight remarkable anxiolytic and prosocial effects of intranasally administered OT in humans, including increased ‘trust’, decreased amygdala activation towards fear-inducing stimuli, improved recognition of social cues and increased gaze directed towards the eye regions of others (Kirsch et al., 2005; Kosfeld et al., 2005; Domes et al., 2006; Guastella et al., 2008)